Cargando…

Insights into Asymmetric Liposomes as a Potential Intervention for Drug Delivery Including Pulmonary Nanotherapeutics

Liposome-based drug delivery systems are nanosized spherical lipid bilayer carriers that can encapsulate a broad range of small drug molecules (hydrophilic and hydrophobic drugs) and large drug molecules (peptides, proteins, and nucleic acids). They have unique characteristics, such as a self-assemb...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Badri, Yaqeen Nadheer, Chaw, Cheng Shu, Elkordy, Amal Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867527/
https://www.ncbi.nlm.nih.gov/pubmed/36678922
http://dx.doi.org/10.3390/pharmaceutics15010294
_version_ 1784876364024774656
author Al Badri, Yaqeen Nadheer
Chaw, Cheng Shu
Elkordy, Amal Ali
author_facet Al Badri, Yaqeen Nadheer
Chaw, Cheng Shu
Elkordy, Amal Ali
author_sort Al Badri, Yaqeen Nadheer
collection PubMed
description Liposome-based drug delivery systems are nanosized spherical lipid bilayer carriers that can encapsulate a broad range of small drug molecules (hydrophilic and hydrophobic drugs) and large drug molecules (peptides, proteins, and nucleic acids). They have unique characteristics, such as a self-assembling bilayer vesicular structure. There are several FDA-approved liposomal-based medicines for treatment of cancer, bacterial, and viral infections. Most of the FDA-approved liposomal-based therapies are in the form of conventional “symmetric” liposomes and they are administered mainly by injection. Arikace(®) is the first and only FDA-approved liposomal-based inhalable therapy (amikacin liposome inhalation suspension) to treat only adults with difficult-to-treat Mycobacterium avium complex (MAC) lung disease as a combinational antibacterial treatment. To date, no “asymmetric liposomes” are yet to be approved, although asymmetric liposomes have many advantages due to the asymmetric distribution of lipids through the liposome’s membrane (which is similar to the biological membranes). There are many challenges for the formulation and stability of asymmetric liposomes. This review will focus on asymmetric liposomes in contrast to conventional liposomes as a potential clinical intervention drug delivery system as well as the formulation techniques available for symmetric and asymmetric liposomes. The review aims to renew the research in liposomal nanovesicle delivery systems with particular emphasis on asymmetric liposomes as future potential carriers for enhancing drug delivery including pulmonary nanotherapeutics.
format Online
Article
Text
id pubmed-9867527
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98675272023-01-22 Insights into Asymmetric Liposomes as a Potential Intervention for Drug Delivery Including Pulmonary Nanotherapeutics Al Badri, Yaqeen Nadheer Chaw, Cheng Shu Elkordy, Amal Ali Pharmaceutics Review Liposome-based drug delivery systems are nanosized spherical lipid bilayer carriers that can encapsulate a broad range of small drug molecules (hydrophilic and hydrophobic drugs) and large drug molecules (peptides, proteins, and nucleic acids). They have unique characteristics, such as a self-assembling bilayer vesicular structure. There are several FDA-approved liposomal-based medicines for treatment of cancer, bacterial, and viral infections. Most of the FDA-approved liposomal-based therapies are in the form of conventional “symmetric” liposomes and they are administered mainly by injection. Arikace(®) is the first and only FDA-approved liposomal-based inhalable therapy (amikacin liposome inhalation suspension) to treat only adults with difficult-to-treat Mycobacterium avium complex (MAC) lung disease as a combinational antibacterial treatment. To date, no “asymmetric liposomes” are yet to be approved, although asymmetric liposomes have many advantages due to the asymmetric distribution of lipids through the liposome’s membrane (which is similar to the biological membranes). There are many challenges for the formulation and stability of asymmetric liposomes. This review will focus on asymmetric liposomes in contrast to conventional liposomes as a potential clinical intervention drug delivery system as well as the formulation techniques available for symmetric and asymmetric liposomes. The review aims to renew the research in liposomal nanovesicle delivery systems with particular emphasis on asymmetric liposomes as future potential carriers for enhancing drug delivery including pulmonary nanotherapeutics. MDPI 2023-01-15 /pmc/articles/PMC9867527/ /pubmed/36678922 http://dx.doi.org/10.3390/pharmaceutics15010294 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Al Badri, Yaqeen Nadheer
Chaw, Cheng Shu
Elkordy, Amal Ali
Insights into Asymmetric Liposomes as a Potential Intervention for Drug Delivery Including Pulmonary Nanotherapeutics
title Insights into Asymmetric Liposomes as a Potential Intervention for Drug Delivery Including Pulmonary Nanotherapeutics
title_full Insights into Asymmetric Liposomes as a Potential Intervention for Drug Delivery Including Pulmonary Nanotherapeutics
title_fullStr Insights into Asymmetric Liposomes as a Potential Intervention for Drug Delivery Including Pulmonary Nanotherapeutics
title_full_unstemmed Insights into Asymmetric Liposomes as a Potential Intervention for Drug Delivery Including Pulmonary Nanotherapeutics
title_short Insights into Asymmetric Liposomes as a Potential Intervention for Drug Delivery Including Pulmonary Nanotherapeutics
title_sort insights into asymmetric liposomes as a potential intervention for drug delivery including pulmonary nanotherapeutics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867527/
https://www.ncbi.nlm.nih.gov/pubmed/36678922
http://dx.doi.org/10.3390/pharmaceutics15010294
work_keys_str_mv AT albadriyaqeennadheer insightsintoasymmetricliposomesasapotentialinterventionfordrugdeliveryincludingpulmonarynanotherapeutics
AT chawchengshu insightsintoasymmetricliposomesasapotentialinterventionfordrugdeliveryincludingpulmonarynanotherapeutics
AT elkordyamalali insightsintoasymmetricliposomesasapotentialinterventionfordrugdeliveryincludingpulmonarynanotherapeutics